156 related articles for article (PubMed ID: 9226235)
1. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260.
Mimura Y; Ogura T; Hayakawa N; Otsuka F; Hashimoto M; Yamauchi T; Makino H; Ogawa N
Nephron; 1997; 76(3):331-6. PubMed ID: 9226235
[TBL] [Abstract][Full Text] [Related]
2. Alterations of renal V1 and V2 receptors in spontaneously hypertensive rats and DOCA-salt hypertensive rats using computerized quantification for macro-autoradiogram.
Mimura Y; Ogura T; Kataoka H; Oishi T; Asano N; Kishida M; Yamauchi T; Ogawa N; Makino H
Res Commun Mol Pathol Pharmacol; 1997 Jan; 95(1):43-56. PubMed ID: 9055348
[TBL] [Abstract][Full Text] [Related]
3. Blocking effects of OPC-21268 and OPC-31260 (vasopressin V1- and V2-receptor antagonists) on vasopressin-induced constrictions in isolated, perfused dog femoral arteries.
Chiba S; Tsukada M
Jpn J Pharmacol; 1992 May; 59(1):133-5. PubMed ID: 1324373
[TBL] [Abstract][Full Text] [Related]
4. Effects of an orally active vasopressin V1 receptor antagonist.
Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
[TBL] [Abstract][Full Text] [Related]
5. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M
Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
[TBL] [Abstract][Full Text] [Related]
7. Different cellular mechanisms of vasopressin receptor V1 and V2 subtype in vasopressin-induced adenosine 3', 5'-monophosphate formation in an immortalized renal tubule cell line, TKC2.
Takeuchi K; Yanai N; Takahashi N; Abe T; Tsutsumi E; Obinata M; Abe K
Biochem Biophys Res Commun; 1994 Jul; 202(2):680-7. PubMed ID: 8048937
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
[TBL] [Abstract][Full Text] [Related]
9. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
[TBL] [Abstract][Full Text] [Related]
10. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney.
Hirata Y; Hayakawa H; Kakoki M; Tojo A; Suzuki E; Nagata D; Kimura K; Goto A; Kikuchi K; Nagano T; Hirobe M; Omata M
Hypertension; 1997 Jan; 29(1 Pt 1):58-64. PubMed ID: 9039081
[TBL] [Abstract][Full Text] [Related]
11. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
Nakamura T; Sakamaki T; Kurashina T; Hoshino J; Sato K; Ono Z; Murata K
Life Sci; 1994; 55(4):PL67-72. PubMed ID: 8028441
[TBL] [Abstract][Full Text] [Related]
12. Vascular responses to vasopressin antagonists in man and rat.
Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
[TBL] [Abstract][Full Text] [Related]
13. Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries.
Chiba S; Tsukada M
Eur J Pharmacol; 1992 Oct; 221(2-3):393-5. PubMed ID: 1330628
[TBL] [Abstract][Full Text] [Related]
14. Human internal mammary artery responses to non-peptide vasopressin antagonists.
Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI
Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263
[TBL] [Abstract][Full Text] [Related]
15. Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands.
Phillips PA; Abrahams JM; Kelly JM; Mooser V; Trinder D; Johnston CI
Endocrinology; 1990 Mar; 126(3):1478-84. PubMed ID: 2307115
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct.
Yoshitomi K; Naruse M; Hanaoka K; Yamamura Y; Imai M; Kurokawa K
Kidney Int Suppl; 1996 Jun; 55():S177-82. PubMed ID: 8743549
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T
Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020
[TBL] [Abstract][Full Text] [Related]
18. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats.
Okada H; Suzuki H; Kanno Y; Yamamura Y; Saruta T
Clin Sci (Lond); 1994 Apr; 86(4):399-404. PubMed ID: 8168333
[TBL] [Abstract][Full Text] [Related]
19. Chronic and selective vasopressin blockade in spontaneously hypertensive rats.
Okada H; Suzuki H; Kanno Y; Yamamura Y; Saruta T
Am J Physiol; 1994 Dec; 267(6 Pt 2):R1467-71. PubMed ID: 7810754
[TBL] [Abstract][Full Text] [Related]
20. The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats.
Fujita H; Yoshiyama M; Takeuchi K; Omura T; Yamagishi H; Iwao H; Miura K; Yoshikawa J
Jpn J Pharmacol; 1998 Oct; 78(2):229-32. PubMed ID: 9829627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
